Published in J Aerosol Med Pulm Drug Deliv on April 01, 2010
Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system. J Aerosol Med Pulm Drug Deliv (2010) 0.78
Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis. Eur J Med Res (2010) 0.77
Advances in device and formulation technologies for pulmonary drug delivery. AAPS PharmSciTech (2014) 0.77
Faraday instability-based micro droplet ejection for inhalation drug delivery. Technology (Singap World Sci) (2014) 0.76
Inhalation drug delivery devices: technology update. Med Devices (Auckl) (2015) 0.76
Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature. Drug Des Devel Ther (2017) 0.75
High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros (2008) 2.40
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 2.05
alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J (2006) 1.98
Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med (2007) 1.29
Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA. J Aerosol Med Pulm Drug Deliv (2010) 1.26
Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J (2008) 1.17
Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci (2000) 1.13
Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J (2009) 1.09
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol (2006) 0.99
Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. Eur Respir J (2003) 0.94
Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung (1990) 0.90
Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis. J Aerosol Med Pulm Drug Deliv (2010) 0.89
Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med (2005) 0.87
Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients. J Aerosol Med (2005) 0.83
Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest (2000) 0.83
Controlled inhalation of aerosolised therapeutics. Expert Opin Drug Deliv (2005) 0.82
Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. Pediatr Crit Care Med (2013) 2.04
Primary use of the venovenous approach for extracorporeal membrane oxygenation in pediatric acute respiratory failure. Pediatr Crit Care Med (2003) 1.94
A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J Pharm Sci (2010) 0.94
The authors reply. Pediatr Crit Care Med (2014) 0.75